Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Steven Cohen's 6 Best Performing Stocks That Still Have Big Upside
Buybacks And Dividends In One ETF
Your Daily Pharma Scoop: Exelixis Still Attractive, Portola's BevyxXa, Pluristem Patent (Seeking Alpha)
Related AMGN
Portfolio Manager Says Now Is A Great Time To Buy Biotech
A Big Biotech ETF Is About To Get Cheaper
Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018 (Seeking Alpha)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!

Partner Center